46 / 88
46
Scientific Programme /
Tuesday, 20 June 2017
WFSBP 2017
TUE
SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM
13:15–14:45
Auditorium 12
Actelion Satellite Symposium
Please see page 78
ES-02
EDUCATIONAL SESSION
14:00–18:00
B3 M1-M2
Pharmacological treatment and non-invasive brain
stimulation
Chair:
Florence Thibaut, France
Chair:
Frederico Garcia, Brazil
001
Evidence-based treatment of anxiety disorders
Borwin Bandelow, Germany
002
Pharmacological treatment of bipolar disorders
Andrew A. Nierenberg, USA
003
Efficacy and safety of antipsychotics in children
and adolescents with severe mental disorders
Christoph U. Correll, USA
004
TDCS (Transcranial Direct Current Stimulation)
and TMS (repetitive Transcranial Magnetic Stimulation)
Shirley Fecteau, Canada
Jerome Brunelin, France
Start of workshop
T43: SCHIZOPHRENIA: BASIC/ CLINICAL
TFS-05
WFSBP TASK FORCE SYMPOSIUM
15:00–16:30
Congress Hall A 3
Biomarkers for schizophrenia: From molecules to brain
function. A consensus of the WFSBP Task Force on
biological markers
Chair:
Andrea Schmitt, Germany
Co-Chair: Daniel Martins de Souza, Brazil
001
Genetic biomarkers
Dan Rujescu, Germany
002
Neuroimaging biomarkers
Joseph Kambeitz, Germany
003
Molecular biomarkers
Daniel Martins de Souza, Brazil
004
Cognition biomarkers
Peter Falkai, Germany
T13: EMERGENCY PSYCHIATRY
TFW-02
WFSBP TASK FORCE WORKSHOP
15:00–16:30
Auditorium 12
WFSBP Consensus on the management of agitation in
psychiatry
Chair:
Siegfried Kasper, Austria
Co-Chair: Eduard Vieta, Spain
001
Agitation: Causes and differential diagnosis
Marina Garriga, Spain
002
Agitation in schizophrenia
Dieter Naber, Germany
003
Agitation in Bipolar Disorder (BP)
Lakshmi Yatham, Canada
004
WFSBP Consensus on agitation in psychiatry
Eduard Vieta, Spain
T1: ADDICTIVE DISORDERS
S-39
SYMPOSIUM
15:00–16:30
Auditorium 10
Current research on the use of cannabinoids
Chair:
Aviv Weinstein, Israel
Co-Chair: Amine Benyamina, France
001
Cannabis use disorder and its effects on cognitive
function
Valerie Curran, United Kingdom
002
The relationship between cannabis and psychosis
Deepak Cyril D'Souza, USA
003
The genetics of cannabis use disorder
Amine Benyamina, France
004
The effects of chronic use of synthetic canna-
binoids on executive brain function
Aviv Weinstein, Israel
T10: DEMENTIA: BASIC/ CLINICAL
S-40
SYMPOSIUM
15:00–16:30
Auditorium 11
Alzheimer's Disease (AD) pathophysiology, prevention
and treatment strategies: Where we stand and where
we go?
Chair:
Jerzy Leszek, Poland
Co-Chair: Ramón Cacabelos, Spain
001
Pharmacogenetics of cerebrovascular phenotypes
of risk in dementia
Ramón Cacabelos, Spain